Purdue Pharma Exits Bankruptcy as Knoa Pharma Nonprofit

Purdue Pharma Transforms into Nonprofit Knoa Pharma

Purdue Pharma has officially ceased operations and concluded its Chapter 11 bankruptcy, re-emerging as a new nonprofit entity named Knoa Pharma. This transition finalizes a $7.4 billion settlement designed to use all company resources to combat the U.S. opioid crisis.

Background of the Restructuring

The company filed for bankruptcy in 2019 after facing thousands of lawsuits regarding its role in fueling the opioid epidemic. Purdue has twice pleaded guilty to federal charges concerning the marketing of its powerful painkiller OxyContin, which led to this court-ordered restructuring.

Financial and Social Impact

Most of the settlement funds will be allocated to state and local governments to mitigate the public costs of opioid addiction. Additionally, $865 million is specifically earmarked for individual claimants. Knoa Pharma will now focus on producing and distributing overdose reversal and addiction treatment medicines at or below cost.

Concluding Outlook

Knoa Pharma's new board, comprising public health and government experts, will oversee its mission to provide care and save lives. This marks a pivotal shift from a for-profit pharmaceutical manufacturer to a public benefit company focused entirely on addressing the crisis it helped create.

FAQ

Q: What is Knoa Pharma?

A: Knoa Pharma is the new nonprofit organization that has emerged from Purdue Pharma's bankruptcy, dedicated to fighting the opioid crisis.

Q: How will the settlement funds be distributed?

A: The $7.4 billion settlement will primarily go to state and local governments, with $865 million reserved for individual victims of the opioid epidemic.

Source: Investing.com